We are preparing the requested document. Please wait, this may take a while...!
|Antigen||Tumor Necrosis Factor Receptor Superfamily, Member 25 (TNFRSF25) Antibodies|
|Epitope||Extracellular Domain Alternatives|
|Reactivity||Human, Mouse (Murine) Alternatives|
|Conjugate||This TNFRSF25 antibody is un-conjugated Alternatives|
Enzyme Immunoassay (EIA), Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Western Blotting (WB)
|Supplier||Log in to see|
Product Details anti-TNFRSF25 AntibodyTarget Details TNFRSF25 Application Details Handling Images
Species reactivity (expected):Mouse.
Species reactivity (tested):Human.
|Immunogen||Synthetic peptide corresponding to amino acids in extracellular domain (ED) of Human DR3 precursor.|
Target Details TNFRSF25Product Details anti-TNFRSF25 Antibody Application Details Handling Images back to top
|Alternative Name||TNFRSF25 / DR3 / TRAMP (TNFRSF25 Antibody Abstract)|
|Background||Apoptosis, or programmed cell death, occurs during normal cellular differentiation and development of multicellular organisms. Apoptosis is induced by certain cytokines including TNF and Fas ligand of the TNF family, through their death domain containing receptors TNFR1 and Fas. A cell surface receptor with a death domain, DR3, has been identified by several groups independently, although it has been given alternative names. The ligand for DR3 has very recently been identified as TWEAK, also termed Apo3L. DR3 is highly expressed in tissues enriched in lymphocytes including PBL, thymus and spleen. DR3 mediates activation of NF kappa B, and induces apoptosis. DR3 may also play a role in regulating lymphocyte homeostasis.Synonyms: AIR, APO3, Apo-3, Apoptosis-inducing receptor AIR, Apoptosis-mediating receptor DR3, Apoptosis-mediating receptor TRAMP, DDR3, Death receptor 3, LARD, Lymphocyte-associated receptor of death, Protein WSL, Protein WSL-1, TNFRSF12, Tumor necrosis factor receptor superfamily member 25, WSL, WSL1|
Application DetailsProduct Details anti-TNFRSF25 Antibody Target Details TNFRSF25 Handling Images back to top
ELISA. Western blot: 1/500-1/1000. Immunocytochemistry: 10 μg/mL. Immunohistochemistry on Paraffin Sections: 3 μg/mL. This antibody was validated for use in immunohistochemistry on a panel of 21formalin-fixed, paraffin-embedded (FFPE) human tissues after heat induced antigenretrieval in pH 6.0 citrate buffer. After incubation with the primary antibody, slides wereincubated with biotinylated secondary antibody, followed by alkalinephosphatase-streptavidin and chromogen.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.
|Restrictions||For Research Use only|
HandlingProduct Details anti-TNFRSF25 Antibody Target Details TNFRSF25 Application Details Images back to top
|Buffer||PBS containing 0.02 % Sodium Azide as preservative.|
|Precaution of Use||This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.|
|Handling Advice||Avoid repeated freezing and thawing.|
|Storage||4 °C/-20 °C|
|Storage Comment||Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at-20 °C for longer.|
ImagesProduct Details anti-TNFRSF25 Antibody Target Details TNFRSF25 Application Details Handling back to top